Supporters of consumer-directed healthcare options want Congress to increase tax breaks and coverage limits to broaden the appeal of health savings accounts (HSAs) linked to high-deductible health plans. Health insurers and employers back legislation that would expand tax credits and higher HSA contribution limits plus increase flexibility in the use of HSA funds.
Supporters of consumer-directed healthcare options want Congress to increase tax breaks and coverage limits to broaden the appeal of health savings accounts (HSAs) linked to high-deductible health plans. Health insurers and employers back legislation that would expand tax credits and higher HSA contribution limits plus increase flexibility in the use of HSA funds.
Despite current limitations, more than 3 million individuals have signed up for some type of high-deductible health plan, and the number is rising as more employers regard HSAs as an important option for providing affordable health insurance.
In addition, the Centers for Medicare and Medicaid Services (CMS) is encouraging HSAs with a new demonstration project that allows Medicare Advantage (MA) plans to offer HSA-like medical savings accounts (MSAs).
CMS will pay for a high-deductible plan plus fund an account established for the beneficiary to pay for allowable health services (unused funds in the account can be rolled over to the next year). Unlike the existing MSA option that no one uses, demonstration MSAs would have flexibility to limit enrollees' out-of-pocket costs, to provide coverage for preventive services and to increase payments for sicker patients.
MA plans also have leeway to offer demonstration MSAs only to the employer group market, but these plans must cover a whole state or region. Medicare MSA plans cannot offer Part D prescription drug benefits, but can design a stand-alone drug coverage plan as a complement.
MINIMAL SAVINGS
Critics contend, however, that HSAs fail to boost consumer cost-sharing in a way to make individuals more prudent purchasers of healthcare services and ultimately reduce healthcare spending. According to an analysis by professors Dahlia Remler and Sherry Glied published by Health Affairs, HSAs rely on high deductibles (around $2,500 a year) to influence spending and have little effect on the large number of low spenders who never reach the deductible limit, or on the very small number of high spenders who exceed the deductible fairly quickly.
The debate is intensifying as policymakers weigh options for revising tax benefits linked to these plans, which were expanded by the Medicare Modernization Act of 2003.
Some skeptics fear that HSAs will undermine the current employer-based health benefit system. Even employers are divided: about one-fourth fear that such plans discourage individuals from seeking needed care, according to a survey by Aon consulting, while half do believe that consumer-driven health plans will make individuals more efficient purchasers of care.
At a June hearing of the House Ways & Means Committee, Jeffrey Cava, executive vice president at Wendy's International, refuted the charge that high-deductible plans discourage preventive care, noting that 75% of his employees received annual physicals during the first year the company made HSAs available.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More